Colin MD - Eiger Biopharmaceutica Sr Operations
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Insider
Colin MD is Sr Operations of Eiger Biopharmaceuticals
| Age | 66 |
| Phone | 650 272 6138 |
| Web | https://www.eigerbio.com |
Eiger Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.5244) % which means that it has lost $0.5244 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2593) %, meaning that it created substantial loss on money invested by shareholders. Eiger Biopharmaceutica's management efficiency ratios could be used to measure how well Eiger Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Eiger Biopharmaceuticals currently holds 41.2 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Eiger Biopharmaceuticals has a current ratio of 7.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eiger Biopharmaceutica's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Angela MD | Spero Therapeutics | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Randi MD | Werewolf Therapeutics | 68 | |
| John CPA | Unicycive Therapeutics | 62 | |
| MA MS | Inozyme Pharma | N/A | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Donald MBA | Lyra Therapeutics | 70 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| James Brady | Spero Therapeutics | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Adam Hansard | Applied Therapeutics | 47 | |
| Richard Hameister | Coherus BioSciences | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
Management Performance
| Return On Equity | -2.26 | |||
| Return On Asset | -0.52 |
Eiger Biopharmaceuticals Leadership Team
Elected by the shareholders, the Eiger Biopharmaceutica's board of directors comprises two types of representatives: Eiger Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eiger. The board's role is to monitor Eiger Biopharmaceutica's management team and ensure that shareholders' interests are well served. Eiger Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eiger Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sriram MBA, Chief Officer | ||
| James JD, Chief Counsel | ||
| Christopher Kurtz, Chief Officer | ||
| Ingrid Choong, VP Devel | ||
| Colleen MD, Senior Diseases | ||
| Erik Atkisson, Corp Counsel | ||
| MBA MD, CEO Director | ||
| William CPA, CFO Officer | ||
| Rich MBA, VP Affairs | ||
| Colin MD, Sr Operations | ||
| MBA III, Chief Officer | ||
| MBBS MD, Senior Operations | ||
| MBA MBA, President, Founder | ||
| Dr JD, Consultant |
Eiger Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eiger Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.26 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (5.28) % | |||
| Current Valuation | 3.88 M | |||
| Shares Outstanding | 1.48 M | |||
| Shares Owned By Insiders | 11.79 % | |||
| Shares Owned By Institutions | 43.86 % | |||
| Number Of Shares Shorted | 29.81 K | |||
| Price To Earning | (2.04) X | |||
| Price To Book | 0.87 X |
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
Moving against Eiger Stock
| 0.8 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.77 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.76 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.7 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.68 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |